FTase-IN-1

Cat. No.:	HY-149015
CAS No.:	2490538-41-3
Molecular Formula:	$C_{23}H_{16}N_2O_2S$
Molecular Weight:	384.45
Target:	Farnesyl Transferase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	FTase-IN-1 (compound 17a) is a potent and specific inhibitor of fanesyl transferase (FTase) with an IC_{50} of 0.35 μM. FTase-IN-1 displays cytotoxicity potential and antitumor activity[1].
IC_{50} & Target	IC50: 0.35 μM (fanesyl transferase)[1]
In Vitro	FTase-IN-1 (compound 17a) (10 μM, 48 h) is an inhibitors of farnesyl transferase (FTase) and inhibits NCI-60 cells proliferation in vitro[1]. FTase-IN-1 (10 μM, 48 h) arrests the cell growth of multiple cancer cell lines with GI_{50} range from 1.8 to 6.5 nM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	NCI-H522 (lung cancer), COLO-205 and HT29 (colon cancer), SF-539 (human glioblastoma), MDA-MB-435 (melanoma), OVCAR-3 (ovarian cancer) and A498 (renal cancer)
Concentration:	10 μM
Incubation Time:	48 hours
Result:	Inhibited cell growth and showed strong antitumor activity.

REFERENCES

[1]. Iuliana-Monica Moise, et al. Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity. Bioorg Chem. 2020 Oct; 103: 104184.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA